<!DOCTYPE html>
<html lang="tr"><head>
<script src="kanserin-ozellikleri-1_files/libs/clipboard/clipboard.min.js"></script>
<script src="kanserin-ozellikleri-1_files/libs/quarto-html/tabby.min.js"></script>
<script src="kanserin-ozellikleri-1_files/libs/quarto-html/popper.min.js"></script>
<script src="kanserin-ozellikleri-1_files/libs/quarto-html/tippy.umd.min.js"></script>
<link href="kanserin-ozellikleri-1_files/libs/quarto-html/tippy.css" rel="stylesheet">
<link href="kanserin-ozellikleri-1_files/libs/quarto-html/light-border.css" rel="stylesheet">
<link href="kanserin-ozellikleri-1_files/libs/quarto-html/quarto-html.min.css" rel="stylesheet" data-mode="light">
<link href="kanserin-ozellikleri-1_files/libs/quarto-html/quarto-syntax-highlighting.css" rel="stylesheet" id="quarto-text-highlighting-styles"><meta charset="utf-8">
  <meta name="generator" content="quarto-1.3.340">

  <meta name="author" content="Serdar BalcÄ±">
  <title>Title</title>
  <meta name="apple-mobile-web-app-capable" content="yes">
  <meta name="apple-mobile-web-app-status-bar-style" content="black-translucent">
  <meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=1.0, user-scalable=no, minimal-ui">
  <link rel="stylesheet" href="kanserin-ozellikleri-1_files/libs/revealjs/dist/reset.css">
  <link rel="stylesheet" href="kanserin-ozellikleri-1_files/libs/revealjs/dist/reveal.css">
  <style>
    code{white-space: pre-wrap;}
    span.smallcaps{font-variant: small-caps;}
    div.columns{display: flex; gap: min(4vw, 1.5em);}
    div.column{flex: auto; overflow-x: auto;}
    div.hanging-indent{margin-left: 1.5em; text-indent: -1.5em;}
    ul.task-list{list-style: none;}
    ul.task-list li input[type="checkbox"] {
      width: 0.8em;
      margin: 0 0.8em 0.2em -1em; /* quarto-specific, see https://github.com/quarto-dev/quarto-cli/issues/4556 */ 
      vertical-align: middle;
    }
  </style>
  <link rel="stylesheet" href="kanserin-ozellikleri-1_files/libs/revealjs/dist/theme/quarto.css" id="theme">
  <link href="kanserin-ozellikleri-1_files/libs/revealjs/plugin/quarto-line-highlight/line-highlight.css" rel="stylesheet">
  <link href="kanserin-ozellikleri-1_files/libs/revealjs/plugin/reveal-menu/menu.css" rel="stylesheet">
  <link href="kanserin-ozellikleri-1_files/libs/revealjs/plugin/reveal-menu/quarto-menu.css" rel="stylesheet">
  <link href="kanserin-ozellikleri-1_files/libs/revealjs/plugin/quarto-support/footer.css" rel="stylesheet">
  <style type="text/css">

  .callout {
    margin-top: 1em;
    margin-bottom: 1em;  
    border-radius: .25rem;
  }

  .callout.callout-style-simple { 
    padding: 0em 0.5em;
    border-left: solid #acacac .3rem;
    border-right: solid 1px silver;
    border-top: solid 1px silver;
    border-bottom: solid 1px silver;
    display: flex;
  }

  .callout.callout-style-default {
    border-left: solid #acacac .3rem;
    border-right: solid 1px silver;
    border-top: solid 1px silver;
    border-bottom: solid 1px silver;
  }

  .callout .callout-body-container {
    flex-grow: 1;
  }

  .callout.callout-style-simple .callout-body {
    font-size: 1rem;
    font-weight: 400;
  }

  .callout.callout-style-default .callout-body {
    font-size: 0.9rem;
    font-weight: 400;
  }

  .callout.callout-titled.callout-style-simple .callout-body {
    margin-top: 0.2em;
  }

  .callout:not(.callout-titled) .callout-body {
      display: flex;
  }

  .callout:not(.no-icon).callout-titled.callout-style-simple .callout-content {
    padding-left: 1.6em;
  }

  .callout.callout-titled .callout-header {
    padding-top: 0.2em;
    margin-bottom: -0.2em;
  }

  .callout.callout-titled .callout-title  p {
    margin-top: 0.5em;
    margin-bottom: 0.5em;
  }
    
  .callout.callout-titled.callout-style-simple .callout-content  p {
    margin-top: 0;
  }

  .callout.callout-titled.callout-style-default .callout-content  p {
    margin-top: 0.7em;
  }

  .callout.callout-style-simple div.callout-title {
    border-bottom: none;
    font-size: .9rem;
    font-weight: 600;
    opacity: 75%;
  }

  .callout.callout-style-default  div.callout-title {
    border-bottom: none;
    font-weight: 600;
    opacity: 85%;
    font-size: 0.9rem;
    padding-left: 0.5em;
    padding-right: 0.5em;
  }

  .callout.callout-style-default div.callout-content {
    padding-left: 0.5em;
    padding-right: 0.5em;
  }

  .callout.callout-style-simple .callout-icon::before {
    height: 1rem;
    width: 1rem;
    display: inline-block;
    content: "";
    background-repeat: no-repeat;
    background-size: 1rem 1rem;
  }

  .callout.callout-style-default .callout-icon::before {
    height: 0.9rem;
    width: 0.9rem;
    display: inline-block;
    content: "";
    background-repeat: no-repeat;
    background-size: 0.9rem 0.9rem;
  }

  .callout-title {
    display: flex
  }
    
  .callout-icon::before {
    margin-top: 1rem;
    padding-right: .5rem;
  }

  .callout.no-icon::before {
    display: none !important;
  }

  .callout.callout-titled .callout-body > .callout-content > :last-child {
    margin-bottom: 0.5rem;
  }

  .callout.callout-titled .callout-icon::before {
    margin-top: .5rem;
    padding-right: .5rem;
  }

  .callout:not(.callout-titled) .callout-icon::before {
    margin-top: 1rem;
    padding-right: .5rem;
  }

  /* Callout Types */

  div.callout-note {
    border-left-color: #4582ec !important;
  }

  div.callout-note .callout-icon::before {
    background-image: url('data:image/png;base64,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');
  }

  div.callout-note.callout-style-default .callout-title {
    background-color: #dae6fb
  }

  div.callout-important {
    border-left-color: #d9534f !important;
  }

  div.callout-important .callout-icon::before {
    background-image: url('data:image/png;base64,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');
  }

  div.callout-important.callout-style-default .callout-title {
    background-color: #f7dddc
  }

  div.callout-warning {
    border-left-color: #f0ad4e !important;
  }

  div.callout-warning .callout-icon::before {
    background-image: url('data:image/png;base64,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');
  }

  div.callout-warning.callout-style-default .callout-title {
    background-color: #fcefdc
  }

  div.callout-tip {
    border-left-color: #02b875 !important;
  }

  div.callout-tip .callout-icon::before {
    background-image: url('data:image/png;base64,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');
  }

  div.callout-tip.callout-style-default .callout-title {
    background-color: #ccf1e3
  }

  div.callout-caution {
    border-left-color: #fd7e14 !important;
  }

  div.callout-caution .callout-icon::before {
    background-image: url('data:image/png;base64,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');
  }

  div.callout-caution.callout-style-default .callout-title {
    background-color: #ffe5d0
  }

  </style>
  <style type="text/css">
    .reveal div.sourceCode {
      margin: 0;
      overflow: auto;
    }
    .reveal div.hanging-indent {
      margin-left: 1em;
      text-indent: -1em;
    }
    .reveal .slide:not(.center) {
      height: 100%;
      overflow-y: auto;
    }
    .reveal .slide.scrollable {
      overflow-y: auto;
    }
    .reveal .footnotes {
      height: 100%;
      overflow-y: auto;
    }
    .reveal .slide .absolute {
      position: absolute;
      display: block;
    }
    .reveal .footnotes ol {
      counter-reset: ol;
      list-style-type: none; 
      margin-left: 0;
    }
    .reveal .footnotes ol li:before {
      counter-increment: ol;
      content: counter(ol) ". "; 
    }
    .reveal .footnotes ol li > p:first-child {
      display: inline-block;
    }
    .reveal .slide ul,
    .reveal .slide ol {
      margin-bottom: 0.5em;
    }
    .reveal .slide ul li,
    .reveal .slide ol li {
      margin-top: 0.4em;
      margin-bottom: 0.2em;
    }
    .reveal .slide ul[role="tablist"] li {
      margin-bottom: 0;
    }
    .reveal .slide ul li > *:first-child,
    .reveal .slide ol li > *:first-child {
      margin-block-start: 0;
    }
    .reveal .slide ul li > *:last-child,
    .reveal .slide ol li > *:last-child {
      margin-block-end: 0;
    }
    .reveal .slide .columns:nth-child(3) {
      margin-block-start: 0.8em;
    }
    .reveal blockquote {
      box-shadow: none;
    }
    .reveal .tippy-content>* {
      margin-top: 0.2em;
      margin-bottom: 0.7em;
    }
    .reveal .tippy-content>*:last-child {
      margin-bottom: 0.2em;
    }
    .reveal .slide > img.stretch.quarto-figure-center,
    .reveal .slide > img.r-stretch.quarto-figure-center {
      display: block;
      margin-left: auto;
      margin-right: auto; 
    }
    .reveal .slide > img.stretch.quarto-figure-left,
    .reveal .slide > img.r-stretch.quarto-figure-left  {
      display: block;
      margin-left: 0;
      margin-right: auto; 
    }
    .reveal .slide > img.stretch.quarto-figure-right,
    .reveal .slide > img.r-stretch.quarto-figure-right  {
      display: block;
      margin-left: auto;
      margin-right: 0; 
    }
  </style>
</head>
<body class="quarto-light">
  <div class="reveal">
    <div class="slides">

<section id="title-slide" class="quarto-title-block center">
  <h1 class="title">Title</h1>

<div class="quarto-title-authors">
<div class="quarto-title-author">
<div class="quarto-title-author-name">
Serdar BalcÄ± 
</div>
</div>
</div>

</section>
<section id="hallmarks-of-cancer" class="title-slide slide level1 center">
<h1>Hallmarks of Cancer</h1>

</section>

<section id="kanserin-ayÄ±rÄ±cÄ±-Ã¶zellikleri" class="title-slide slide level1 center">
<h1>Kanserin ayÄ±rÄ±cÄ± Ã¶zellikleri</h1>

</section>

<section id="kanser-nedir" class="title-slide slide level1 center">
<h1>Kanser nedir?</h1>
<p><strong>A neoplasm is an abnormal mass of tissue, the growth of which exceeds and is uncoordinated with that of the normal tissues and persists in the same excessive manner after cessation of the stimuli which evoked the change</strong></p>
<p><strong>Disorder of cell growth that is triggered by a series of acquired mutations affecting a single cell and its clonal progeny</strong></p>

<img data-src="./img-local/Kanserin-Ozellikleri-10.jpg" class="r-stretch"></section>

<section id="kanserin-baÅlÄ±ca-Ã¶zellikleri-1" class="title-slide slide level1 center">
<h1>Kanserin BaÅlÄ±ca Ãzellikleri-1</h1>

</section>

<section id="dr.-serdar-balci" class="title-slide slide level1 center">
<h1>Dr.&nbsp;Serdar BALCI</h1>
<p><img data-src="./img-local/Kanserin-Ozellikleri-11.jpg"></p>
<p><img data-src="./img-local/Kanserin-Ozellikleri-12.png"></p>
<p><img data-src="./img-local/Kanserin-Ozellikleri-13.png"></p>
<p><img data-src="./img-local/Kanserin-Ozellikleri-14.png"></p>
<p><strong>Cell. 2000 Jan 7;100(1):57-70.</strong></p>
<p><img data-src="./img-local/Kanserin-Ozellikleri-15.jpg"></p>
<p><img data-src="./img-local/Kanserin-Ozellikleri-16.png"></p>
<p><span style="color:#FFFFFF"> <em>Cell</em> </span> <span style="color:#FFFFFF">&nbsp;2011 144, 646-674DOI: (10.1016/j.cell.2011.02.013) </span></p>
<p><strong>Cell. 2011 Mar 4;144(5):646-74</strong></p>
<p><span style="color:#FFFFFF">Copyright Â© 2011 Elsevier Inc.</span> <em><a href="http://www.elsevier.com/termsandconditions">Terms and Conditions</a></em></p>
<p><img data-src="./img-local/Kanserin-Ozellikleri-17.jpg"></p>
<p><img data-src="./img-local/Kanserin-Ozellikleri-18.png"></p>
<p><span style="color:#FFFFFF"> <em>Cell</em> </span> <span style="color:#FFFFFF">&nbsp;2011 144, 646-674DOI: (10.1016/j.cell.2011.02.013) </span></p>
<p><strong>Cell. 2011 Mar 4;144(5):646-74</strong></p>
<p><span style="color:#FFFFFF">Copyright Â© 2011 Elsevier Inc.</span> <em><a href="http://www.elsevier.com/termsandconditions">Terms and Conditions</a></em></p>
<p><img data-src="./img-local/Kanserin-Ozellikleri-19.png"></p>
<p><strong>Cell. 2000 Jan 7;100(1):57-70.</strong></p>
<p><img data-src="./img-local/Kanserin-Ozellikleri-110.jpg"></p>
<p><img data-src="./img-local/Kanserin-Ozellikleri-111.png"></p>
<p><span style="color:#FFFFFF"> <em>Cell</em> </span> <span style="color:#FFFFFF">&nbsp;2011 144, 646-674DOI: (10.1016/j.cell.2011.02.013) </span></p>
<p><strong>Cell. 2011 Mar 4;144(5):646-74</strong></p>
<p><span style="color:#FFFFFF">Copyright Â© 2011 Elsevier Inc.</span> <em><a href="http://www.elsevier.com/termsandconditions">Terms and Conditions</a></em></p>
<p><img data-src="./img-local/Kanserin-Ozellikleri-112.png"></p>
<p><strong>Cell. 2000 Jan 7;100(1):57-70.</strong></p>
<p><img data-src="./img-local/Kanserin-Ozellikleri-113.jpg"></p>
<p><img data-src="./img-local/Kanserin-Ozellikleri-114.png"></p>
<p><span style="color:#FFFFFF"> <em>Cell</em> </span> <span style="color:#FFFFFF">&nbsp;2011 144, 646-674DOI: (10.1016/j.cell.2011.02.013) </span></p>
<p><strong>Cell. 2011 Mar 4;144(5):646-74</strong></p>
<p><span style="color:#FFFFFF">Copyright Â© 2011 Elsevier Inc.</span> <em><a href="http://www.elsevier.com/termsandconditions">Terms and Conditions</a></em></p>
<p><img data-src="./img-local/Kanserin-Ozellikleri-115.png"></p>
<p><strong>Cell. 2000 Jan 7;100(1):57-70.</strong></p>
<p><img data-src="./img-local/Kanserin-Ozellikleri-116.jpg"></p>
<p><img data-src="./img-local/Kanserin-Ozellikleri-117.png"></p>
<p><span style="color:#FFFFFF"> <em>Cell</em> </span> <span style="color:#FFFFFF">&nbsp;2011 144, 646-674DOI: (10.1016/j.cell.2011.02.013) </span></p>
<p><strong>Cell. 2011 Mar 4;144(5):646-74</strong></p>
<p><span style="color:#FFFFFF">Copyright Â© 2011 Elsevier Inc.</span> <em><a href="http://www.elsevier.com/termsandconditions">Terms and Conditions</a></em></p>
<p><img data-src="./img-local/Kanserin-Ozellikleri-118.jpg"></p>
<p><img data-src="./img-local/Kanserin-Ozellikleri-119.png"></p>
<p><span style="color:#FFFFFF"> <em>Cell</em> </span> <span style="color:#FFFFFF">&nbsp;2011 144, 646-674DOI: (10.1016/j.cell.2011.02.013) </span></p>
<p><strong>Cell. 2011 Mar 4;144(5):646-74</strong></p>
<p><span style="color:#FFFFFF">Copyright Â© 2011 Elsevier Inc.</span> <em><a href="http://www.elsevier.com/termsandconditions">Terms and Conditions</a></em></p>
</section>

<section id="section" class="title-slide slide level1 center">
<h1></h1>
<p><strong>http://www.cellsignal.com/common/content/content.jsp?id=science-pathways</strong></p>

<img data-src="./img-local/Kanserin-Ozellikleri-120.png" class="r-stretch"><p><strong>Robbins Basic Pathology</strong></p>
</section>

<section id="kanserin-baÅlÄ±ca-Ã¶zellikleri" class="title-slide slide level1 center">
<h1>Kanserin BaÅlÄ±ca Ãzellikleri</h1>
<p><strong>Proliferasyon sinyalleri bakÄ±mÄ±ndan kendi kendine yeterli olmak</strong></p>
<p><strong>HuÌcre buÌyuÌmesini inhibe eden sinyaller karÅÄ±sÄ±nda duyarsÄ±zlÄ±k</strong></p>
<p><strong>Apoptozdan kaÃ§Ä±Å</strong></p>
<p><strong>SÄ±nÄ±rsÄ±z replikasyon potansiyeli</strong></p>
<p><strong>SuÌrekli anjiyogenez</strong></p>
<p><strong>DokularÄ± invaze etme ve dokularda metastaz yapma yeteneÄi</strong></p>
<p><strong>Genomdaki dengesizlik</strong></p>
<p><strong>TÃ¼mÃ¶rÃ¼ uyaran inflamasyon</strong></p>

<img data-src="./img-local/Kanserin-Ozellikleri-121.jpg" class="r-stretch"></section>

<section id="bÃ¼yÃ¼me-sinyalleri-bakimindan-kendi-kendine-yeterli-olmak" class="title-slide slide level1 center">
<h1>BÃYÃME SINYALLERI BAKIMINDAN KENDI KENDINE YETERLI OLMAK</h1>
<p><img data-src="./img-local/Kanserin-Ozellikleri-122.jpg"></p>
<p><img data-src="./img-local/Kanserin-Ozellikleri-123.jpg"></p>
<p><img data-src="./img-local/Kanserin-Ozellikleri-124.png"></p>
<p><img data-src="./img-local/Kanserin-Ozellikleri-125.jpg"></p>
<p><img data-src="./img-local/Kanserin-Ozellikleri-126.jpg"></p>
<p><img data-src="./img-local/Kanserin-Ozellikleri-127.jpg"></p>
<p><img data-src="./img-local/Kanserin-Ozellikleri-128.jpg"></p>
<p><img data-src="./img-local/Kanserin-Ozellikleri-129.jpg"></p>
<p><img data-src="./img-local/Kanserin-Ozellikleri-130.jpg"></p>
<p><img data-src="./img-local/Kanserin-Ozellikleri-131.jpg"></p>
<p><img data-src="./img-local/Kanserin-Ozellikleri-132.jpg"></p>
<p><img data-src="./img-local/Kanserin-Ozellikleri-133.jpg"></p>
<p><img data-src="./img-local/Kanserin-Ozellikleri-134.jpg"></p>
<p><img data-src="./img-local/Kanserin-Ozellikleri-135.jpg"></p>
<p><img data-src="./img-local/Kanserin-Ozellikleri-136.jpg"></p>
<p><img data-src="./img-local/Kanserin-Ozellikleri-137.jpg"></p>
<p><img data-src="./img-local/Kanserin-Ozellikleri-138.jpg"></p>
</section>

<section id="bÃ¼yÃ¼me-sinyalleri-bakÄ±mÄ±ndan-kendi-kendine-yeterli-olmak" class="title-slide slide level1 center">
<h1>BÃ¼yÃ¼me sinyalleri bakÄ±mÄ±ndan kendi kendine yeterli olmak</h1>
<ul>
<li><strong>Fizyolojik BÃ¼yÃ¼me</strong>
<ul>
<li><strong>BÃ¼yÃ¼me faktÃ¶rÃ¼, hÃ¼cre zarÄ±ndaki spesifik reseptÃ¶re baÄlanÄ±r</strong></li>
<li><strong>BÃ¼yÃ¼me faktÃ¶rÃ¼ reseptÃ¶rÃ¼ geÃ§ici ve kÄ±sÄ±tlÄ± olarak aktif hale gelir, zarÄ±n iÃ§ yÃ¼zÃ¼ndeki sinyal ileten proteinleri aktive eder</strong></li>
<li><strong>Ä°kincil haberciler ve sinyal ileten bir dizi molekÃ¼l ile sinyal Ã§ekirdeÄe iletilir</strong></li>
<li><strong>DNA transkripsiyonunu aktive eden nÃ¼kleer dÃ¼zenleyici faktÃ¶rler uyarÄ±lÄ±r ve aktif hale gelir</strong></li>
<li><strong>HÃ¼cre siklusu baÅlar ve hÃ¼cre bÃ¶lÃ¼nmesi gerÃ§ekleÅir</strong></li>
</ul></li>
</ul>

<img data-src="./img-local/Kanserin-Ozellikleri-139.png" class="r-stretch"><p><strong>Robbins Basic Pathology</strong></p>
</section>

<section id="bÃ¼yÃ¼me-faktÃ¶rleri" class="title-slide slide level1 center">
<h1>BÃ¼yÃ¼me FaktÃ¶rleri</h1>
<ul>
<li><strong>Kanser hÃ¼creleri kendilerini uyaracak bÃ¼yÃ¼me faktÃ¶rleri sentezlerler</strong></li>
<li><strong>Glioblastom</strong>
<ul>
<li><strong>Platelet kÃ¶kenli bÃ¼yÃ¼me faktÃ¶rÃ¼ (PDGF) sentezler</strong></li>
<li><strong>PDGF reseptÃ¶rÃ¼ eksprese ederler</strong></li>
</ul></li>
<li><strong>Sarkomlar</strong>
<ul>
<li><strong>Transforming growth factor-Î± (TGF-Î±) sentezler</strong></li>
<li><strong>TGF-Î± reseptÃ¶r</strong></li>
</ul></li>
<li><strong>Stroma ile iliÅkiler</strong>
<ul>
<li><strong>TÃ¼mÃ¶r hÃ¼creleri, stromal hÃ¼creleri uyaran sinyaller gÃ¶nderir</strong></li>
<li><strong>Stroma hÃ¼creleri de tÃ¼mÃ¶rÃ¼ uyaran bÃ¼yÃ¼me faktÃ¶rleri sentezler</strong></li>
</ul></li>
</ul>
</section>

<section id="bÃ¼yÃ¼me-faktÃ¶rÃ¼-reseptÃ¶rleri-ve-reseptÃ¶r-olmayan-tirozin-kinazlar" class="title-slide slide level1 center">
<h1>BÃ¼yÃ¼me faktÃ¶rÃ¼ reseptÃ¶rleri ve reseptÃ¶r olmayan tirozin kinazlar</h1>
<p><strong>Mutant reseptÃ¶r proteinleri:</strong></p>
<p><strong>HÃ¼creleri sÃ¼rekli mitoz iÃ§in uyaran sinyaller Ã¼retir</strong></p>
<p><strong>Bu uyarÄ± ortamda bÃ¼yÃ¼me faktÃ¶rÃ¼ olmasa da olur</strong></p>
<ul>
<li><strong>BÃ¼yÃ¼me faktÃ¶rÃ¼ reseptÃ¶rÃ¼nÃ¼n aÅÄ±rÄ± ekspresyonu</strong>
<ul>
<li><strong>Normalde proliferasyonu uyarmayacak dÃ¼ÅÃ¼k dozdaki bÃ¼yÃ¼me faktÃ¶rÃ¼ne duyarlÄ±</strong></li>
</ul></li>
<li><strong>ERBB1 (EGF reseptÃ¶rÃ¼)</strong>
<ul>
<li><strong>AkciÄer skuamÃ¶z hÃ¼creli karsinomlarÄ±n %80âinde aÅÄ±rÄ± ekspresyon</strong></li>
<li><strong>GlioblastomlarÄ±n %50âsi</strong></li>
<li><strong>BaÅ boyun epitelyal tÃ¼mÃ¶rlerinin %80-100âÃ¼nde</strong></li>
</ul></li>
<li><strong>HER2/NEU (ERBB2)</strong>
<ul>
<li><strong>Meme kanserlerinin %35-30âunda amplifiye</strong></li>
<li><strong>AkciÄer, over ve tÃ¼krÃ¼k bezi adenokarsinomlarÄ±nda</strong></li>
<li><strong>KÃ¼Ã§Ã¼k miktardaki bÃ¼yÃ¼me faktÃ¶rÃ¼ ile mitoz uyarÄ±lÄ±r</strong></li>
<li><strong>Meme kanserinde yÃ¼ksek miktarda HER2/NEU protein varlÄ±ÄÄ± kÃ¶tÃ¼ prognoz</strong></li>
<li><strong>Anti-HER2/NEU antikorlar meme kanseri tedavisinde kullanÄ±lÄ±yor</strong></li>
</ul></li>
</ul>
</section>

<section id="ilerleme-yÃ¶nÃ¼nde-sinyal-ileten-proteinler" class="title-slide slide level1 center">
<h1>Ä°lerleme yÃ¶nÃ¼nde sinyal ileten proteinler</h1>
<ul>
<li><strong>UyarÄ±yÄ± reseptÃ¶rden alÄ±rlar</strong></li>
<li><strong>UyarÄ±yÄ± nÃ¼kleusa taÅÄ±rlar</strong>
<ul>
<li><strong>Ä°kinci haberciler</strong></li>
<li><strong>Bir dizi fosforilasyon</strong></li>
</ul></li>
<li><strong>EÄer bu uyarÄ±larda otonomi geliÅirse, Ã§ekirdeÄe sÃ¼rekli uyaran aktarÄ±lÄ±r</strong></li>
<li><strong>RAS</strong></li>
<li><strong>ABL</strong></li>
</ul>
</section>

<section id="ras-protein" class="title-slide slide level1 center">
<h1>RAS protein</h1>
<ul>
<li><strong>Ä°nsan tÃ¼mÃ¶rlerinde en Ã§ok mutasyona uÄrayan proto-onkogen</strong></li>
<li><strong>TÃ¼m tÃ¼mÃ¶rlerin %30âu RAS mutasyonu iÃ§erir</strong></li>
<li><strong>Kolon ve pankreas karsinomlarÄ±nda daha sÄ±ktÄ±r</strong></li>
<li><strong>G protein</strong>
<ul>
<li><strong>GTP ile fosforile olur</strong></li>
</ul></li>
</ul>

<img data-src="./img-local/Kanserin-Ozellikleri-140.png" class="r-stretch"></section>

<section id="ras" class="title-slide slide level1 center">
<h1>RAS</h1>
<ul>
<li><strong>Normal</strong>
<ul>
<li><strong>GTPâye baÄlandÄ±ÄÄ±nda aktif</strong></li>
<li><strong>GTPase ile inaktif hale dÃ¶ner</strong></li>
<li><strong>GTPase-activating proteins (GAPs)</strong></li>
</ul></li>
<li><strong>Mutasyonda</strong>
<ul>
<li><strong>Defosforile olamaz</strong></li>
<li><strong>SÃ¼rekli aktif kalÄ±r</strong></li>
</ul></li>
</ul>
<p><strong>Robbins Basic Pathology</strong></p>

<img data-src="./img-local/Kanserin-Ozellikleri-141.png" class="r-stretch"></section>

<section id="gaps" class="title-slide slide level1 center">
<h1>GAPs</h1>
<ul>
<li><strong>GTPase-activating protein</strong></li>
<li><strong>Neurofibromin-1 (NF-1)</strong>
<ul>
<li><strong>Fonksiyon kaybÄ±na neden olan mutasyon olduÄunda</strong></li>
<li><strong>RAS aktif kalÄ±r</strong></li>
<li><strong>Neurofibromatozis hastalÄ±ÄÄ± geliÅir</strong></li>
</ul></li>
</ul>
<p><strong>Robbins Basic Pathology</strong></p>

<img data-src="./img-local/Kanserin-Ozellikleri-142.png" class="r-stretch"></section>

<section id="raferkmap-kinaz-yolaÄÄ±" class="title-slide slide level1 center">
<h1>RAF/ERK/MAP kinaz yolaÄÄ±</h1>
<p><strong>MelanomlarÄ±n %60âÄ±nda aktif</strong></p>
<p><strong>BRAF mutasyonu papiller tiroid karsinomlarÄ±nda gÃ¶rÃ¼lÃ¼r</strong></p>
<p><strong>Robbins Basic Pathology</strong></p>
</section>

<section id="abl" class="title-slide slide level1 center">
<h1>ABL</h1>
<ul>
<li><strong>ReseptÃ¶r iliÅkisiz tirozin kinaz</strong></li>
<li><strong>Kronik Myelojenik LÃ¶semi</strong>
<ul>
<li><strong>ABL Chr9âdan Chr22âye translokasyon olur</strong></li>
<li><strong>BCR ile birleÅir</strong></li>
<li><strong>SÃ¼rekli aktivasyon</strong></li>
<li><strong>RAS yolaÄÄ±nÄ± da aktive der</strong></li>
</ul></li>
<li><strong>Hedefe yÃ¶nelik tedavilerin ilki</strong>
<ul>
<li><strong>BCR-ABL kinaz inhibitÃ¶rÃ¼ (Gleevec)</strong></li>
</ul></li>
</ul>

<img data-src="./img-local/Kanserin-Ozellikleri-143.png" class="r-stretch"><p><strong>Robbins and Cotranâs Pathological Basis of Diseases</strong></p>
</section>

<section id="nÃ¼kleer-transkripsiyon-faktÃ¶rleri" class="title-slide slide level1 center">
<h1>NÃ¼kleer Transkripsiyon FaktÃ¶rleri</h1>
<ul>
<li><strong>MYC, MYB, JUN, FOS, ve REL onkogenleri</strong>
<ul>
<li><strong>BÃ¼yÃ¼meyi uyaran genlerin (Cyclin) ekspresyonlarÄ±nÄ± dÃ¼zenlerler</strong></li>
</ul></li>
</ul>
</section>

<section id="myc" class="title-slide slide level1 center">
<h1>MYC</h1>
<ul>
<li><strong>BÃ¼yÃ¼meyi uyaran Siklin baÄÄ±mlÄ± kinazlarÄ± aktive eder (cyclin-dependent kinases, CDKs)</strong></li>
<li><strong>CDK inhibitÃ¶rlerini (CDKIs) baskÄ±larlar</strong></li>
<li><strong>Aerobik glikolize neden olan genleri aktive ederler (Warburg etkisi)</strong></li>
<li><strong>Glutamin kullanÄ±mÄ±nÄ± arttÄ±rÄ±rlar</strong></li>
<li><strong>Translokasyon</strong>
<ul>
<li><strong>t(8;14) Burkitt lenfoma</strong></li>
</ul></li>
<li><strong>Amplifikasyon</strong>
<ul>
<li><strong>Meme, kolon, akciÄer</strong></li>
<li><strong>NÃ¶roblastom, AkciÄer kÃ¼Ã§Ã¼k hÃ¼creli karsinom (NMYC, LMYC)</strong></li>
</ul></li>
</ul>
<p><img data-src="./img-local/Kanserin-Ozellikleri-144.png"></p>
<p><strong>Robbins and Cotranâs Pathological Basis of Diseases</strong></p>
<p><img data-src="./img-local/Kanserin-Ozellikleri-145.png"></p>
<p><strong>Robbins and Cotranâs Pathological Basis of Diseases</strong></p>
<p><img data-src="./img-local/Kanserin-Ozellikleri-146.jpg"></p>
</section>

<section id="siklin-ve-siklin-baÄÄ±mlÄ±-kinazlar" class="title-slide slide level1 center">
<h1>Siklin ve siklin baÄÄ±mlÄ± kinazlar</h1>
<ul>
<li><strong>Kontrol noktalarÄ±</strong></li>
<li><strong>G0 â G1</strong></li>
<li><strong>G1 â S</strong>
<ul>
<li><strong>KÄ±sÄ±tlama noktasÄ±</strong></li>
<li><strong>HÄ±z kÄ±sÄ±tlayÄ±cÄ± basamak</strong></li>
</ul></li>
</ul>
<p><strong>Kontrol noktalarÄ± anormal DNA proliferasyonunu engeller</strong></p>
<p><img data-src="./img-local/Kanserin-Ozellikleri-147.png"></p>
<p><strong>Robbins Basic Pathology</strong></p>
<ul>
<li><strong>Neoplazilerde CyclinD veya CDK4 ekspresyonlarÄ± sÄ±ktÄ±r</strong></li>
<li><strong>Cyclin D</strong>
<ul>
<li><strong>Meme, Ã¶zefagus, karaciÄer, lenfomalar, plazma hÃ¼cre neoplazileri</strong></li>
</ul></li>
<li><strong>CDK4</strong>
<ul>
<li><strong>Melanomlar, sarkomlar, glioblastomlar</strong></li>
</ul></li>
<li><strong>CDKI</strong>
<ul>
<li><strong>ÃoÄu malignitede mutasyon veya gen susturulmasÄ± ile inaktiftir</strong></li>
<li><strong>CDKN2A germ hÃ¼cre mutasyonunda</strong>
<ul>
<li><strong>%25âinde melanom yatkÄ±nlÄ±ÄÄ±</strong></li>
</ul></li>
<li><strong>Somatik akkiz delesyon veya inaktivasyonu</strong></li>
</ul></li>
</ul>
<p><img data-src="./img-local/Kanserin-Ozellikleri-148.png"></p>
<p><strong>Robbins Basic Pathology</strong></p>
</section>

<section id="homework" class="title-slide slide level1 center">
<h1>Homework</h1>
<p><strong>Rous sarcoma virus</strong></p>

<img data-src="./img-local/Kanserin-Ozellikleri-149.jpg" class="r-stretch"></section>

<section id="bÃ¼yÃ¼me-inhibitÃ¶rlerine-duyarsizlik" class="title-slide slide level1 center">
<h1>BÃYÃME INHIBITÃRLERINE DUYARSIZLIK</h1>

</section>

<section id="rb-geni-hÃ¼cre-siklusunun-yÃ¶neticisi" class="title-slide slide level1 center">
<h1>RB geni: HÃ¼cre siklusunun yÃ¶neticisi</h1>
<ul>
<li><strong>13q14</strong></li>
<li><strong>Retinoblastoma hem sporadik hem de ailesel formda benzer Åekilde gÃ¶rÃ¼lÃ¼r</strong></li>
<li><strong>Ailesel formu otozomal dominanttÄ±r</strong></li>
<li><strong>RB geninin homozigot kaybÄ±</strong>
<ul>
<li><strong>Meme kanseri, KÃ¼Ã§Ã¼k hÃ¼creli akciÄer kanseri ve mesane kanseri</strong></li>
</ul></li>
<li><strong>Retinoblastom hastalarÄ± osteosarkom ve yumuÅak doku sarkomlarÄ± iÃ§in artmÄ±Å risk taÅÄ±r</strong></li>
</ul>
</section>

<section id="retinoblastom" class="title-slide slide level1 center">
<h1>Retinoblastom</h1>
<p><img data-src="./img-local/Kanserin-Ozellikleri-150.jpg"></p>
<p><img data-src="./img-local/Kanserin-Ozellikleri-151.jpg"></p>
<p><img data-src="./img-local/Kanserin-Ozellikleri-152.jpg"></p>
<p><img data-src="./img-local/Kanserin-Ozellikleri-153.jpg"></p>
<p><strong>Figure 2, from Pediatr Radiol. Jun 2012; 42(6): 738â749. PMCID: PMC3530407</strong></p>
<p><img data-src="./img-local/Kanserin-Ozellikleri-154.jpg"></p>
<p><strong>Figure 7.4b </strong> _ The Biology of Cancer_ __ (Â© Garland Science 2007)__</p>
</section>

<section id="knudson-Ã§ift-darbe-hipotezi" class="title-slide slide level1 center">
<h1>Knudson Ã§ift darbe hipotezi</h1>
<p><img data-src="./img-local/Kanserin-Ozellikleri-155.png"></p>
<p><strong>Robbins Basic Pathology</strong></p>
<p><img data-src="./img-local/Kanserin-Ozellikleri-156.png"></p>
<p><strong>Robbins Basic Pathology</strong></p>
</section>

<section id="sadece-bir-rb-geni-mutant-ise-hÃ¼cre-neoplastik-olur-mu" class="title-slide slide level1 center">
<h1>Sadece bir Rb geni mutant ise hÃ¼cre neoplastik olur mu?</h1>
<p><strong>HayÄ±r</strong></p>
<p><strong>TÃ¼mÃ¶r BaskÄ±layÄ±cÄ± Genlerin her iki alleli de kaybolursa neoplazi geliÅir</strong></p>
<p><strong>Bir genin fonksiyonunun kaybÄ± hangi mekanizmalar ile olur?</strong></p>
<p><strong>Proto-onkogenin tek alleli mutasyona uÄrarsa neoplazi geliÅir mi?</strong></p>
<p><img data-src="./img-local/Kanserin-Ozellikleri-157.png"></p>
<p><strong>G1 kontrol noktasÄ±</strong></p>
<p><strong>Robbins Basic Pathology</strong></p>
<p><img data-src="./img-local/Kanserin-Ozellikleri-158.png"></p>
<p><strong>G1 kontrol noktasÄ±</strong></p>
<p><strong>cyclin E transkripsiyonu</strong></p>
<p><strong>Robbins Basic Pathology</strong></p>
<p><img data-src="./img-local/Kanserin-Ozellikleri-159.png"></p>
<p><strong>G1 kontrol noktasÄ±</strong></p>
<p><strong>HPV E7 protein mimics here</strong></p>
<p><strong>cyclin E transkripsiyonu</strong></p>
<p><strong>Robbins Basic Pathology</strong></p>
</section>

<section id="tp53-geni-genomun-koruyucusu" class="title-slide slide level1 center">
<h1>TP53 GeniGenomun Koruyucusu</h1>
<ul>
<li><strong>Sessizlik</strong>
<ul>
<li><strong>GeÃ§ici olarak hÃ¼cre siklusunun durdurulmasÄ±</strong></li>
</ul></li>
<li><strong>YaÅlÄ±lÄ±k</strong>
<ul>
<li><strong>KalÄ±cÄ± hÃ¼cre siklus durdurulmasÄ±</strong></li>
</ul></li>
<li><strong>Apoptoz</strong>
<ul>
<li><strong>ProgramlanmÄ±Å hÃ¼cre Ã¶lÃ¼mÃ¼nÃ¼n baÅlamasÄ±</strong></li>
</ul></li>
</ul>
<p><strong>Rb dÄ±Å uyaranlara, p53 iÃ§ uyaranlara cevap verir</strong></p>
</section>

<section id="p53-aktivasyonuna-neden-olanlar" class="title-slide slide level1 center">
<h1>p53 aktivasyonuna neden olanlar</h1>
<p><strong>Anoksi</strong></p>
<p><strong>Uygunsuz onkojenik protein aktivasyonu</strong></p>
<p><strong>DNA bÃ¼tÃ¼nlÃ¼ÄÃ¼nÃ¼n hasara uÄramasÄ±</strong></p>
<p><strong>p53 bir DNA hasar cevabÄ± proteinidir</strong></p>
</section>

<section id="p53" class="title-slide slide level1 center">
<h1>p53</h1>
<ul>
<li><strong>Normal</strong>
<ul>
<li><strong>KÄ±sa bir yarÄ± Ã¶mrÃ¼ var</strong></li>
<li><strong>20 dakika iÃ§inde MDM2 ile birleÅir ve parÃ§alanÄ±r</strong></li>
</ul></li>
<li><strong>Stres durumunda</strong>
<ul>
<li><strong>Protein kinazlar aktive olur</strong>
<ul>
<li><strong>ATM (ataxia telangiectasia mutated)</strong></li>
</ul></li>
<li><strong>P53âte post-transkripsiyon deÄiÅikliklere neden olur</strong></li>
<li><strong>P53 MDM2âden ayrÄ±lÄ±r</strong></li>
<li><strong>p53 aktivitesi devam eder</strong></li>
</ul></li>
<li><strong>Tamir sonrasÄ±</strong>
<ul>
<li><strong>P53, MDM2 ekspresyonunu uyarÄ±r, p53 normal seviyelere dÃ¶ner ve hÃ¼cre siklusu devam eder</strong></li>
</ul></li>
</ul>

<img data-src="./img-local/Kanserin-Ozellikleri-160.png" class="r-stretch"><p><strong>Robbins Basic Pathology</strong></p>
</section>

<section id="p53-kontrolÃ¼nde-hÃ¼cre-siklusunda-durma" class="title-slide slide level1 center">
<h1>p53 kontrolÃ¼nde hÃ¼cre siklusunda durma</h1>
<p><strong>P53, CDKI ekspresyonunu saÄlar: CDKN1A (p21)</strong></p>
<p><strong>p21 protein, cyclinâCDK complekslerini inhibe eder</strong></p>
<p><strong>Rb fosforilasyonunu engeller</strong></p>
<p><strong>G1 fazÄ±nda hÃ¼cre siklusu durur</strong></p>
<p><strong>DNA hasarÄ±nÄ± tamir etmeye vakit kalÄ±r</strong></p>
</section>

<section id="p53-nedenli-yaÅlÄ±lÄ±k-senescence" class="title-slide slide level1 center">
<h1>p53 nedenli yaÅlÄ±lÄ±k (senescence)</h1>
<p><strong>Global kromatin deÄiÅiklikleri</strong></p>
<p><strong>Gen ekspresyonu kalÄ±cÄ± olarak durur</strong></p>
<p><strong>HÃ¼cre siklusunda kalÄ±cÄ± blok oluÅur</strong></p>
</section>

<section id="p53-nedenli-apoptoz" class="title-slide slide level1 center">
<h1>p53 nedenli apoptoz</h1>
<p><strong>KalÄ±cÄ± DNA hasarÄ±</strong></p>
<p><strong>Pro-apoptotik genler (BAX ve PUMA) aktif olur</strong></p>
</section>

<section id="p53-1" class="title-slide slide level1 center">
<h1>p53</h1>
<ul>
<li><strong>Kanserlerin %70âinde p53âÃ¼n her iki allelinde kayÄ±p vardÄ±r</strong></li>
<li><strong>DiÄerlerinde TP53âÃ¼n Ã¼st ve altÄ±ndaki yolaklarda hasar vardÄ±r</strong></li>
<li><strong>p53 onkojenik DNA virÃ¼sleri ile inhibe olur</strong>
<ul>
<li><strong>Hepatit B</strong></li>
<li><strong>EBV</strong></li>
</ul></li>
</ul>
</section>

<section id="li-fraumeni-sendromu" class="title-slide slide level1 center">
<h1>Li-Fraumeni sendromu</h1>
<p><strong>Mutant TP53 alleli kalÄ±tÄ±lÄ±r</strong></p>
<p><strong>50 yaÅ civarÄ±nda kanser riskinde 25x artÄ±Å</strong></p>
<p><strong>Sarkomlar, meme kanseri, lÃ¶semi, beyin tÃ¼mÃ¶rleri, adrenal corteks karsinomlarÄ±</strong></p>
<p><strong>GenÃ§ yaÅta</strong></p>
<p><strong>Ãok sayÄ±da primer tÃ¼mÃ¶r</strong></p>
</section>

<section id="transforming-growth-factor-Î²-yolaÄÄ±" class="title-slide slide level1 center">
<h1>Transforming Growth Factor-Î² YolaÄÄ±</h1>
<ul>
<li><strong>Proliferasyonun belirgin inhibitÃ¶rÃ¼</strong></li>
<li><strong>TGF-Î² ReseptÃ¶r I ve II</strong>
<ul>
<li><strong>Dimerizasyon ile aktive olur</strong></li>
</ul></li>
<li><strong>BÃ¼yÃ¼me engelleyici aktivite</strong>
<ul>
<li><strong>CDKI transkripsiyonunu</strong></li>
</ul></li>
<li><strong>BÃ¼yÃ¼meyi uyaran genlerin baskÄ±lanmasÄ±</strong>
<ul>
<li><strong>MYC, CDK2, CDK4</strong></li>
<li><strong>Cyclin A ve E</strong></li>
</ul></li>
<li><strong>SMAD molekÃ¼lleri</strong>
<ul>
<li><strong>Antiproliferatif sinyalleri reseptÃ¶rden nÃ¼kleusa taÅÄ±r</strong></li>
</ul></li>
<li><strong>TGF-Î² sinyali ile epitelyal-mezenkimal dÃ¶nÃ¼ÅÃ¼m aktive olur</strong></li>
</ul>

<img data-src="./img-local/Kanserin-Ozellikleri-161.jpg" class="r-stretch"><p><strong>Figure 5.21 </strong> _ The Biology of Cancer_ __ (Â© Garland Science 2007)__</p>
</section>

<section id="transforming-growth-factor-Î²-yolaÄÄ±ndaki-deÄiÅiklikler" class="title-slide slide level1 center">
<h1>Transforming Growth Factor-Î² YolaÄÄ±ndaki deÄiÅiklikler</h1>
<ul>
<li><strong>Mutasyonlar</strong>
<ul>
<li><strong>TGF-Î² reseptÃ¶r tip II</strong>
<ul>
<li><strong>Kolon, mide, endometrium kanserleri</strong></li>
</ul></li>
<li><strong>SMAD molekÃ¼lÃ¼</strong>
<ul>
<li><strong>SMAD4, pankreas kanserleri</strong></li>
</ul></li>
</ul></li>
<li><strong>Pankreas kanserlerinin %100âÃ¼nde, kolon kanserlerinin %83âÃ¼nde TGF-Î² yolaÄÄ±nda bir mutasyon vardÄ±r</strong></li>
</ul>

<img data-src="./img-local/Kanserin-Ozellikleri-162.jpg" class="r-stretch"><p><strong>Figure 6.29d </strong> _ The Biology of Cancer_ __ (Â© Garland Science 2007)__</p>
</section>

<section id="kontakt-inhibisyon" class="title-slide slide level1 center">
<h1>Kontakt inhibisyon</h1>
<ul>
<li><strong>Normal hÃ¼creler kÃ¼ltÃ¼rde bÃ¼yÃ¼tÃ¼ldÃ¼klerinde</strong>
<ul>
<li><strong>BÃ¼yÃ¼me tek bir tabaka oluÅana kadar devam eder</strong></li>
<li><strong>HÃ¼cre- hÃ¼cre baÄlantÄ±larÄ± nedeniyle bundan sonra bÃ¶lÃ¼nme durur</strong></li>
</ul></li>
<li><strong>Kanser hÃ¼crelerinde</strong>
<ul>
<li><strong>Kontakt inhibisyon yoktur</strong></li>
<li><strong>HÃ¼creler bÃ¼yÃ¼meye devam eder, birbiri Ã¼zerine birikmeye devam eder</strong></li>
</ul></li>
</ul>
<p><img data-src="./img-local/Kanserin-Ozellikleri-163.png"></p>
<p><strong>Figure 3.7 from The Biology Of Cancer (2007) - Weinberg</strong></p>
<p><img data-src="./img-local/Kanserin-Ozellikleri-164.jpg"></p>
<p><strong>Figure 3.7a </strong> _ The Biology of Cancer_ __ (Â© Garland Science 2007)__</p>
<p><img data-src="./img-local/Kanserin-Ozellikleri-165.jpg"></p>
<p><strong>Figure 3.12 </strong> _ The Biology of Cancer_ __ (Â© Garland Science 2007)__</p>
<p><img data-src="./img-local/Kanserin-Ozellikleri-166.png"></p>
<p><strong>Figure 3.7 from The Biology Of Cancer (2007) - Weinberg</strong></p>
</section>

<section id="e-cadherin" class="title-slide slide level1 center">
<h1>E-cadherin</h1>
<ul>
<li><strong>E-cadherin epitelyal hÃ¼crelerdeki hÃ¼cre-hÃ¼cre baÄlantÄ±larÄ±nÄ± saÄlar</strong></li>
<li><strong>TÃ¼mÃ¶r supresÃ¶r gen olan NF2 (neurofibromin-2, merlin), E-cadherin baÄÄ±mlÄ± kontakt inhibisyonu aktive eder</strong></li>
<li><strong>NF2ânin homozigot kaybÄ±nda â nÃ¶ral tÃ¼mÃ¶rler geliÅir</strong>
<ul>
<li><strong>NÃ¶rofibromatozis</strong></li>
</ul></li>
<li><strong>E-cadherin, APC tarafÄ±ndan da dÃ¼zenlenir (adenomatous polyposis coli geni)</strong></li>
</ul>
<p><strong>APC yok</strong></p>
<p><strong>Î²-Catenin WNT durumdan baÄÄ±msÄ±z olarak Ã§ekirdeÄe geÃ§er</strong></p>
<p><strong>WNT sinyali APCâyi baskÄ±lar</strong></p>
<p><strong>Î²-Catenin Ã§ekirdeÄe geÃ§er</strong></p>
<p><strong>APC aktif</strong></p>
<p><strong>Î²-Catenin yÄ±kÄ±lÄ±r</strong></p>
<p><img data-src="./img-local/Kanserin-Ozellikleri-167.png"></p>
<p><strong>Robbins Basic Pathology</strong></p>
<p><strong>Î²-Catenin Ã§ekirdekte aktiftir</strong></p>
<p><img data-src="./img-local/Kanserin-Ozellikleri-168.png"></p>
<p><strong>Proliferasyon iÃ§in cyclin D1 ve MYC transkripsiyonu olur</strong></p>
<p><strong>TWIST ve SLUG eksprese edilir</strong></p>
<p><strong>Bunlar E-cadherin ekspresyonunu baskÄ±lar</strong></p>
<p><strong>Kontakt inhibisyon azalÄ±r</strong></p>
<p><strong>Robbins Basic Pathology</strong></p>
</section>

<section id="adenomatous-polyposis-coli" class="title-slide slide level1 center">
<h1>Adenomatous Polyposis Coli</h1>
<ul>
<li><strong>APC bir tÃ¼mÃ¶r baskÄ±layÄ±cÄ± gendir</strong></li>
<li><strong>Tek alleldeki mutasyonda</strong>
<ul>
<li><strong>20 yaÅ civarÄ±nda</strong></li>
<li><strong>Kolonda yÃ¼zlerce, binlerce adenomatÃ¶z polip geliÅir</strong></li>
</ul></li>
<li><strong>DiÄer allel de mutasyona uÄrarsa</strong>
<ul>
<li><strong>Malignite geliÅir</strong></li>
</ul></li>
<li><strong>APC mutasyonlarÄ± sporadik kolon tÃ¼mÃ¶rlerinin %70-80âinde gÃ¶rÃ¼lÃ¼r</strong></li>
<li><strong>Normal APC geni olan kolon kanserlerinde Î²-catenin aktive edici mutasyonlarÄ± gÃ¶rÃ¼lÃ¼r</strong>
<ul>
<li><strong>APCânin yÄ±kÄ±m etkisine direnÃ§ gÃ¶sterecek Åekilde mutasyonlar olur</strong></li>
</ul></li>
</ul>
<p><img data-src="./img-local/Kanserin-Ozellikleri-169.jpg"></p>
<p><strong>Figure 7.22 </strong> _ The Biology of Cancer_ __ (Â© Garland Science 2007)__</p>
<p><img data-src="./img-local/Kanserin-Ozellikleri-170.jpg"></p>
<p><strong>Figure 7.24a </strong> _ The Biology of Cancer_ __ (Â© Garland Science 2007)__</p>
<p><img data-src="./img-local/Kanserin-Ozellikleri-171.jpg"></p>
</section>

<section id="hÃ¼cre-Ã¶lÃ¼mÃ¼nden-kaÃ§iÅ" class="title-slide slide level1 center">
<h1>HÃCRE ÃLÃMÃNDEN KAÃIÅ</h1>

<img data-src="./img-local/Kanserin-Ozellikleri-172.png" class="r-stretch"></section>

<section id="dÄ±Å-yolak" class="title-slide slide level1 center">
<h1>DÄ±Å yolak</h1>
<p><strong>TNF reseptÃ¶rÃ¼ CD95 (Fas) ligandÄ± olan CD95Lâa baÄlanÄ±r</strong></p>
<p><strong>ReseptÃ¶rde trimerizasyon ve Ã¶lÃ¼m grubu ile baÄlanma</strong></p>
<p><strong>FADD baÄlanamsÄ±</strong></p>
<p><strong>Procaspase-8 kÃ¼Ã§Ã¼k fragmanalra bÃ¶lÃ¼nerek aktive olur</strong></p>
<p><strong>Caspase-8 yolaÄÄ±ndaki caspase-3âÃ¼ aktive eder</strong></p>
<p><strong>DNA ve diÄer yapÄ±lar yÄ±kÄ±lÄ±r</strong></p>
<p><strong>HÃ¼cre Ã¶lÃ¼mÃ¼</strong></p>
<p><strong>Robbins Basic Pathology</strong></p>

<img data-src="./img-local/Kanserin-Ozellikleri-173.png" class="r-stretch"></section>

<section id="iÃ§-yolak" class="title-slide slide level1 center">
<h1>Ä°Ã§ yolak</h1>
<p><strong>BÃ¼yÃ¼me faktÃ¶rlerinin kaybÄ±, stres, hasar</strong></p>
<p><strong>Mitokondri dÄ±Å membranÄ±nda geÃ§irgenlik artÄ±ÅÄ±</strong></p>
<p><strong>Cytochrome c sitozole Ã§Ä±kar</strong></p>
<p><strong>APAF-1âe baÄlanÄ±r</strong></p>
<p><strong>caspase-9âu aktive eder</strong></p>
<p><strong>DiÄer kaspazlar aktive edilir</strong></p>
<p><strong>Robbins Basic Pathology</strong></p>
</section>

<section id="intrinsic-yolak-iÃ§-yolak" class="title-slide slide level1 center">
<h1>Intrinsic Yolak (Ä°Ã§ yolak)</h1>
<ul>
<li><strong>Pro-apoptotik proteinler</strong>
<ul>
<li><strong>BAX ve BAK</strong></li>
<li><strong>Mitokondri geÃ§irgenliÄini direk artÄ±rÄ±r</strong></li>
</ul></li>
<li><strong>Anti-apoptotik proteinler</strong>
<ul>
<li><strong>BCL2 ve BCL-XL</strong></li>
<li><strong>BAX ve BAKâÄ± baskÄ±lar</strong></li>
</ul></li>
<li><strong>BH3-only proteinleri</strong>
<ul>
<li><strong>BAD, BID ve PUMA</strong></li>
<li><strong>Pro ve enati-apoptotik genlerdeki dengeyi saÄlar</strong></li>
</ul></li>
</ul>
<p><strong>Robbins Basic Pathology</strong></p>
</section>

<section id="follikÃ¼ler-b-hÃ¼creli-lenfoma" class="title-slide slide level1 center">
<h1>FollikÃ¼ler B HÃ¼creli Lenfoma</h1>
<ul>
<li><strong>t(14;18) (q32;q21) translokasyonu</strong></li>
<li><strong>14q32</strong>
<ul>
<li><strong>Ig aÄÄ±r zincir lokusu</strong></li>
<li><strong>Aktif transkripsiyon sahasÄ±</strong></li>
</ul></li>
<li><strong>18q21</strong>
<ul>
<li><strong>BCL2</strong></li>
</ul></li>
<li><strong>Yanyana geldiklerinde</strong>
<ul>
<li><strong>BCL2 fazla eksprese olur</strong></li>
</ul></li>
<li><strong>B hÃ¼creleri apoptoza gidemez</strong></li>
<li><strong>YavaÅ seyirli tÃ¼mÃ¶rlerdendir</strong>
<ul>
<li><strong>Aktif proliferasyona neden olan bir mutasyon deÄil, Ã¶lÃ¼mÃ¼ engelleyen bir mutasyon olduÄu iÃ§in</strong></li>
</ul></li>
</ul>
</section>

<section id="otofaji" class="title-slide slide level1 center">
<h1>Otofaji</h1>
<ul>
<li><strong>Stres altÄ±nda hÃ¼crenin kendi parÃ§alarÄ±nÄ± tÃ¼ketmesi</strong></li>
<li><strong>Kanser hÃ¼creleri otofajiye engel olan mutasyonlar oluÅturabilir</strong></li>
<li><strong>Kanser hÃ¼creleri uygunsuz ortamlarda yaÅamak iÃ§in otofajiyi kullanabilir</strong>
<ul>
<li><strong>Tedavi gibi</strong></li>
</ul></li>
</ul>

<img data-src="./img-local/Kanserin-Ozellikleri-174.jpg" class="r-stretch"></section>

<section id="sinirsiz-Ã§oÄalma-potansiyeli" class="title-slide slide level1 center">
<h1>SINIRSIZ ÃOÄALMA POTANSIYELI</h1>

</section>

<section id="normal-hÃ¼crelerde-telomerler-kÄ±salÄ±r" class="title-slide slide level1 center">
<h1>Normal hÃ¼crelerde telomerler kÄ±salÄ±r</h1>

<img data-src="./img-local/Kanserin-Ozellikleri-175.png" class="r-stretch"><p><strong>YaklaÅÄ±k 60, 70 bÃ¶lÃ¼nme kapasitesi vardÄ±r</strong></p>
<p><strong>Telomerler kÄ±salÄ±r</strong></p>
<p><strong>DNA tamir mekanizmasÄ± DNA Ã§ift zincir hasarÄ± olarak algÄ±lar</strong></p>
<p><strong>HÃ¼cre yaÅlÄ±lÄ±Äa girer</strong></p>
<p><strong>Robbins Basic Pathology</strong></p>
</section>

<section id="neoplazide-telomer-kÄ±salmasÄ±" class="title-slide slide level1 center">
<h1>Neoplazide telomer kÄ±salmasÄ±</h1>
<p><img data-src="./img-local/Kanserin-Ozellikleri-176.png"></p>
<p><strong>TP53 ve RB mutasyonlarÄ±nda hÃ¼cre Ã§oÄalmaya zorlanÄ±r</strong></p>
<p><strong>Nonhomolog uÃ§ ekleme yapÄ±lÄ±r</strong></p>
<p><strong>KromozomlarÄ±n kÄ±sa uÃ§larÄ± birleÅtirilir</strong></p>
<p><strong>Disentrik kromozomlar oluÅur</strong></p>
<p><strong>Anafazda her iki noktadan Ã§ekim olur</strong></p>
<p><strong>Yeni DNA Ã§ift zincir kayÄ±plarÄ±</strong></p>
<p><strong>Tekrarlayan birleÅmeler ve kÄ±rÄ±klar</strong></p>
<p><strong>Apoptoza gidebilir</strong></p>
<p><strong>Robbins Basic Pathology</strong></p>
<p><img data-src="./img-local/Kanserin-Ozellikleri-177.png"></p>
<p><strong>Rubinâs Pathology 7th Ed</strong></p>
<p><img data-src="./img-local/Kanserin-Ozellikleri-178.png"></p>
<ul>
<li><strong>Hemen tÃ¼m kanserlerde telomer korunmasÄ± gÃ¶rÃ¼lÃ¼r</strong></li>
<li><strong>Telomeraz enzimi fazla Ã§alÄ±ÅÄ±r</strong></li>
<li><strong>Kolon tÃ¼mÃ¶rlerinde</strong>
<ul>
<li><strong>Erken lezyonlarda yÃ¼ksek genomik instabilite, dÃ¼ÅÃ¼k telomeraz aktivitesi</strong></li>
<li><strong>Malignite geliÅtiÄinde, kompleks karyotip ve yÃ¼ksek telomeraz gÃ¶rÃ¼lÃ¼r</strong></li>
</ul></li>
</ul>
<p><strong>Robbins Basic Pathology</strong></p>
<p><img data-src="./img-local/Kanserin-Ozellikleri-179.png"></p>
<p><strong>Robbins Basic Pathology</strong></p>
<div class="footer footer-default">

</div>
</section>
    </div>
  </div>

  <script>window.backupDefine = window.define; window.define = undefined;</script>
  <script src="kanserin-ozellikleri-1_files/libs/revealjs/dist/reveal.js"></script>
  <!-- reveal.js plugins -->
  <script src="kanserin-ozellikleri-1_files/libs/revealjs/plugin/quarto-line-highlight/line-highlight.js"></script>
  <script src="kanserin-ozellikleri-1_files/libs/revealjs/plugin/pdf-export/pdfexport.js"></script>
  <script src="kanserin-ozellikleri-1_files/libs/revealjs/plugin/reveal-menu/menu.js"></script>
  <script src="kanserin-ozellikleri-1_files/libs/revealjs/plugin/reveal-menu/quarto-menu.js"></script>
  <script src="kanserin-ozellikleri-1_files/libs/revealjs/plugin/quarto-support/support.js"></script>
  

  <script src="kanserin-ozellikleri-1_files/libs/revealjs/plugin/notes/notes.js"></script>
  <script src="kanserin-ozellikleri-1_files/libs/revealjs/plugin/search/search.js"></script>
  <script src="kanserin-ozellikleri-1_files/libs/revealjs/plugin/zoom/zoom.js"></script>
  <script src="kanserin-ozellikleri-1_files/libs/revealjs/plugin/math/math.js"></script>
  <script>window.define = window.backupDefine; window.backupDefine = undefined;</script>

  <script>

      // Full list of configuration options available at:
      // https://revealjs.com/config/
      Reveal.initialize({
'controlsAuto': true,
'previewLinksAuto': false,
'smaller': false,
'pdfSeparateFragments': false,
'autoAnimateEasing': "ease",
'autoAnimateDuration': 1,
'autoAnimateUnmatched': true,
'menu': {"side":"left","useTextContentForMissingTitles":true,"markers":false,"loadIcons":false,"custom":[{"title":"Tools","icon":"<i class=\"fas fa-gear\"></i>","content":"<ul class=\"slide-menu-items\">\n<li class=\"slide-tool-item active\" data-item=\"0\"><a href=\"#\" onclick=\"RevealMenuToolHandlers.fullscreen(event)\"><kbd>f</kbd> Fullscreen</a></li>\n<li class=\"slide-tool-item\" data-item=\"1\"><a href=\"#\" onclick=\"RevealMenuToolHandlers.speakerMode(event)\"><kbd>s</kbd> Speaker View</a></li>\n<li class=\"slide-tool-item\" data-item=\"2\"><a href=\"#\" onclick=\"RevealMenuToolHandlers.overview(event)\"><kbd>o</kbd> Slide Overview</a></li>\n<li class=\"slide-tool-item\" data-item=\"3\"><a href=\"#\" onclick=\"RevealMenuToolHandlers.togglePdfExport(event)\"><kbd>e</kbd> PDF Export Mode</a></li>\n<li class=\"slide-tool-item\" data-item=\"4\"><a href=\"#\" onclick=\"RevealMenuToolHandlers.keyboardHelp(event)\"><kbd>?</kbd> Keyboard Help</a></li>\n</ul>"}],"openButton":true},
'smaller': false,
 
        // Display controls in the bottom right corner
        controls: false,

        // Help the user learn the controls by providing hints, for example by
        // bouncing the down arrow when they first encounter a vertical slide
        controlsTutorial: false,

        // Determines where controls appear, "edges" or "bottom-right"
        controlsLayout: 'edges',

        // Visibility rule for backwards navigation arrows; "faded", "hidden"
        // or "visible"
        controlsBackArrows: 'faded',

        // Display a presentation progress bar
        progress: true,

        // Display the page number of the current slide
        slideNumber: false,

        // 'all', 'print', or 'speaker'
        showSlideNumber: 'all',

        // Add the current slide number to the URL hash so that reloading the
        // page/copying the URL will return you to the same slide
        hash: true,

        // Start with 1 for the hash rather than 0
        hashOneBasedIndex: false,

        // Flags if we should monitor the hash and change slides accordingly
        respondToHashChanges: true,

        // Push each slide change to the browser history
        history: true,

        // Enable keyboard shortcuts for navigation
        keyboard: true,

        // Enable the slide overview mode
        overview: true,

        // Disables the default reveal.js slide layout (scaling and centering)
        // so that you can use custom CSS layout
        disableLayout: false,

        // Vertical centering of slides
        center: false,

        // Enables touch navigation on devices with touch input
        touch: true,

        // Loop the presentation
        loop: false,

        // Change the presentation direction to be RTL
        rtl: false,

        // see https://revealjs.com/vertical-slides/#navigation-mode
        navigationMode: 'linear',

        // Randomizes the order of slides each time the presentation loads
        shuffle: false,

        // Turns fragments on and off globally
        fragments: true,

        // Flags whether to include the current fragment in the URL,
        // so that reloading brings you to the same fragment position
        fragmentInURL: false,

        // Flags if the presentation is running in an embedded mode,
        // i.e. contained within a limited portion of the screen
        embedded: false,

        // Flags if we should show a help overlay when the questionmark
        // key is pressed
        help: true,

        // Flags if it should be possible to pause the presentation (blackout)
        pause: true,

        // Flags if speaker notes should be visible to all viewers
        showNotes: false,

        // Global override for autoplaying embedded media (null/true/false)
        autoPlayMedia: null,

        // Global override for preloading lazy-loaded iframes (null/true/false)
        preloadIframes: null,

        // Number of milliseconds between automatically proceeding to the
        // next slide, disabled when set to 0, this value can be overwritten
        // by using a data-autoslide attribute on your slides
        autoSlide: 0,

        // Stop auto-sliding after user input
        autoSlideStoppable: true,

        // Use this method for navigation when auto-sliding
        autoSlideMethod: null,

        // Specify the average time in seconds that you think you will spend
        // presenting each slide. This is used to show a pacing timer in the
        // speaker view
        defaultTiming: null,

        // Enable slide navigation via mouse wheel
        mouseWheel: false,

        // The display mode that will be used to show slides
        display: 'block',

        // Hide cursor if inactive
        hideInactiveCursor: true,

        // Time before the cursor is hidden (in ms)
        hideCursorTime: 5000,

        // Opens links in an iframe preview overlay
        previewLinks: false,

        // Transition style (none/fade/slide/convex/concave/zoom)
        transition: 'none',

        // Transition speed (default/fast/slow)
        transitionSpeed: 'default',

        // Transition style for full page slide backgrounds
        // (none/fade/slide/convex/concave/zoom)
        backgroundTransition: 'none',

        // Number of slides away from the current that are visible
        viewDistance: 3,

        // Number of slides away from the current that are visible on mobile
        // devices. It is advisable to set this to a lower number than
        // viewDistance in order to save resources.
        mobileViewDistance: 2,

        // The "normal" size of the presentation, aspect ratio will be preserved
        // when the presentation is scaled to fit different resolutions. Can be
        // specified using percentage units.
        width: 1050,

        height: 700,

        // Factor of the display size that should remain empty around the content
        margin: 0.1,

        math: {
          mathjax: 'https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.0/MathJax.js',
          config: 'TeX-AMS_HTML-full',
          tex2jax: {
            inlineMath: [['\\(','\\)']],
            displayMath: [['\\[','\\]']],
            balanceBraces: true,
            processEscapes: false,
            processRefs: true,
            processEnvironments: true,
            preview: 'TeX',
            skipTags: ['script','noscript','style','textarea','pre','code'],
            ignoreClass: 'tex2jax_ignore',
            processClass: 'tex2jax_process'
          },
        },

        // reveal.js plugins
        plugins: [QuartoLineHighlight, PdfExport, RevealMenu, QuartoSupport,

          RevealMath,
          RevealNotes,
          RevealSearch,
          RevealZoom
        ]
      });
    </script>
    <script id="quarto-html-after-body" type="application/javascript">
    window.document.addEventListener("DOMContentLoaded", function (event) {
      const toggleBodyColorMode = (bsSheetEl) => {
        const mode = bsSheetEl.getAttribute("data-mode");
        const bodyEl = window.document.querySelector("body");
        if (mode === "dark") {
          bodyEl.classList.add("quarto-dark");
          bodyEl.classList.remove("quarto-light");
        } else {
          bodyEl.classList.add("quarto-light");
          bodyEl.classList.remove("quarto-dark");
        }
      }
      const toggleBodyColorPrimary = () => {
        const bsSheetEl = window.document.querySelector("link#quarto-bootstrap");
        if (bsSheetEl) {
          toggleBodyColorMode(bsSheetEl);
        }
      }
      toggleBodyColorPrimary();  
      const tabsets =  window.document.querySelectorAll(".panel-tabset-tabby")
      tabsets.forEach(function(tabset) {
        const tabby = new Tabby('#' + tabset.id);
      });
      const isCodeAnnotation = (el) => {
        for (const clz of el.classList) {
          if (clz.startsWith('code-annotation-')) {                     
            return true;
          }
        }
        return false;
      }
      const clipboard = new window.ClipboardJS('.code-copy-button', {
        text: function(trigger) {
          const codeEl = trigger.previousElementSibling.cloneNode(true);
          for (const childEl of codeEl.children) {
            if (isCodeAnnotation(childEl)) {
              childEl.remove();
            }
          }
          return codeEl.innerText;
        }
      });
      clipboard.on('success', function(e) {
        // button target
        const button = e.trigger;
        // don't keep focus
        button.blur();
        // flash "checked"
        button.classList.add('code-copy-button-checked');
        var currentTitle = button.getAttribute("title");
        button.setAttribute("title", "KopyalandÄ±");
        let tooltip;
        if (window.bootstrap) {
          button.setAttribute("data-bs-toggle", "tooltip");
          button.setAttribute("data-bs-placement", "left");
          button.setAttribute("data-bs-title", "KopyalandÄ±");
          tooltip = new bootstrap.Tooltip(button, 
            { trigger: "manual", 
              customClass: "code-copy-button-tooltip",
              offset: [0, -8]});
          tooltip.show();    
        }
        setTimeout(function() {
          if (tooltip) {
            tooltip.hide();
            button.removeAttribute("data-bs-title");
            button.removeAttribute("data-bs-toggle");
            button.removeAttribute("data-bs-placement");
          }
          button.setAttribute("title", currentTitle);
          button.classList.remove('code-copy-button-checked');
        }, 1000);
        // clear code selection
        e.clearSelection();
      });
      function tippyHover(el, contentFn) {
        const config = {
          allowHTML: true,
          content: contentFn,
          maxWidth: 500,
          delay: 100,
          arrow: false,
          appendTo: function(el) {
              return el.closest('section.slide') || el.parentElement;
          },
          interactive: true,
          interactiveBorder: 10,
          theme: 'light-border',
          placement: 'bottom-start'
        };
          config['offset'] = [0,0];
          config['maxWidth'] = 700;
        window.tippy(el, config); 
      }
      const noterefs = window.document.querySelectorAll('a[role="doc-noteref"]');
      for (var i=0; i<noterefs.length; i++) {
        const ref = noterefs[i];
        tippyHover(ref, function() {
          // use id or data attribute instead here
          let href = ref.getAttribute('data-footnote-href') || ref.getAttribute('href');
          try { href = new URL(href).hash; } catch {}
          const id = href.replace(/^#\/?/, "");
          const note = window.document.getElementById(id);
          return note.innerHTML;
        });
      }
      const findCites = (el) => {
        const parentEl = el.parentElement;
        if (parentEl) {
          const cites = parentEl.dataset.cites;
          if (cites) {
            return {
              el,
              cites: cites.split(' ')
            };
          } else {
            return findCites(el.parentElement)
          }
        } else {
          return undefined;
        }
      };
      var bibliorefs = window.document.querySelectorAll('a[role="doc-biblioref"]');
      for (var i=0; i<bibliorefs.length; i++) {
        const ref = bibliorefs[i];
        const citeInfo = findCites(ref);
        if (citeInfo) {
          tippyHover(citeInfo.el, function() {
            var popup = window.document.createElement('div');
            citeInfo.cites.forEach(function(cite) {
              var citeDiv = window.document.createElement('div');
              citeDiv.classList.add('hanging-indent');
              citeDiv.classList.add('csl-entry');
              var biblioDiv = window.document.getElementById('ref-' + cite);
              if (biblioDiv) {
                citeDiv.innerHTML = biblioDiv.innerHTML;
              }
              popup.appendChild(citeDiv);
            });
            return popup.innerHTML;
          });
        }
      }
    });
    </script>
    

</body></html>